Key points are not available for this paper at this time.
N6-methyladenosine (m 6 A) is the most prevalent internal RNA modification, especially within eukaryotic messenger RNAs (mRNAs). m 6 A modifications of RNA regulate splicing, translocation, stability, and translation into proteins. m 6 A modifications are catalyzed by RNA methyltransferases, such as METTL3, METTL14, and WTAP (writers); the modifications are removed by the demethylases fat mass and obesity-associated protein (FTO) and ALKBH5 (ALKB homolog 5) (erasers); and the modifications are recognized by m 6 A-binding proteins, such as YTHDF domain-containing proteins and IGF2BPs (readers). Abnormal changes in the m 6 A levels of these genes are closely related to tumor occurrence and development. In this paper, we review the role of m 6 A in human cancer and summarize its prospective applications in cancer.
Zhao et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: